

Joan S Brugge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615428/publications.pdf>

Version: 2024-02-01

53
papers

4,150
citations

159585

30
h-index

182427

51
g-index

59
all docs

59
docs citations

59
times ranked

7981
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts. <i>Oncogene</i> , 2022, 41, 112-124.	5.9	6
2	Abstract P5-01-02: Single cell RNA transcriptomics reveals tumor promoting mammary cell subpopulation upon replication stress in <i>BRCA1</i> mutant breast cancer mouse model. <i>Cancer Research</i> , 2022, 82, P5-01-02-P5-01-02.	0.9	0
3	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 323-339.	28.4	107
4	Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. <i>Nature Protocols</i> , 2021, 16, 1936-1965.	12.0	97
5	Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. <i>PLoS ONE</i> , 2021, 16, e0251163.	2.5	9
6	Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. <i>Science Signaling</i> , 2021, 14, .	3.6	10
7	Cycling cancer persister cells arise from lineages with distinct programs. <i>Nature</i> , 2021, 596, 576-582.	27.8	236
8	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). <i>Nature Communications</i> , 2020, 11, 5824.	12.8	42
9	Transient commensal clonal interactions can drive tumor metastasis. <i>Nature Communications</i> , 2020, 11, 5799.	12.8	30
10	Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 132.	5.0	19
11	3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. <i>Molecular Cell</i> , 2020, 80, 828-844.e6.	9.7	110
12	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , 2020, 38, 829-843.e4.	16.8	40
13	Fibroblast tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16500-16508.	7.1	23
14	Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. <i>Nature Communications</i> , 2020, 11, 1711.	12.8	134
15	Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing. <i>Cell Reports</i> , 2020, 33, 108566.	6.4	75
16	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , 2020, 78, 1096-1113.e8.	9.7	114
17	Characterization of Mammary Cells Coexpressing Separate Lineage Markers. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
18	United They Stand, Divided They Fall. <i>Cell Metabolism</i> , 2019, 30, 624-625.	16.2	3

#	ARTICLE	IF	CITATIONS
19	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 642-655.	4.1	39
20	Role for polo-like kinase 4 in mediation of cytokinesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11309-11318.	7.1	30
21	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	4.1	39
22	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1115-1126.	4.1	20
23	Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. <i>Cell Metabolism</i> , 2019, 29, 1166-1181.e6.	16.2	121
24	CRB3 and the FERM protein EPB41L4B regulate proliferation of mammary epithelial cells through the release of amphiregulin. <i>PLoS ONE</i> , 2018, 13, e0207470.	2.5	3
25	Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. <i>Cancer Cell</i> , 2018, 33, 985-1003.e7.	16.8	184
26	Starved epithelial cells uptake extracellular matrix for survival. <i>Nature Communications</i> , 2017, 8, 13989.	12.8	91
27	Metabolic changes promote rejection of oncogenic cells. <i>Nature Cell Biology</i> , 2017, 19, 414-415.	10.3	6
28	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	174
29	Not just Salk. <i>Science</i> , 2017, 357, 1105-1106.	12.6	4
30	Identification of cancer genes that are independent of dominant proliferation and lineage programs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11276-E11284.	7.1	20
31	Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program <i>in vivo</i> . <i>Npj Breast Cancer</i> , 2017, 3, 18.	5.2	18
32	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clinical Cancer Research</i> , 2017, 23, 1263-1273.	7.0	95
33	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. <i>Nature Communications</i> , 2017, 8, 365.	12.8	44
34	Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. <i>ELife</i> , 2017, 6, .	6.0	55
35	Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells. <i>Cell Metabolism</i> , 2016, 23, 867-880.	16.2	214
36	Cytokinesis involves a nontranscriptional function of the Hippo pathway effector YAP. <i>Science Signaling</i> , 2016, 9, ra23.	3.6	53

#	ARTICLE	IF	CITATIONS
37	ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. <i>Cancer Research</i> , 2016, 76, 7168-7180.	0.9	53
38	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 6039-6050.	7.0	48
39	Coping with the metabolic stress of leaving home. <i>Cell Research</i> , 2016, 26, 757-758.	12.0	5
40	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. <i>JCI Insight</i> , 2016, 1, .	5.0	45
41	Moving Closer To Victory. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 281-288.	1.1	0
42	Signal Transduction in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a006098-a006098.	6.2	665
43	The enemy of my enemy is my friend. <i>Nature</i> , 2015, 527, 170-171.	27.8	47
44	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. <i>Nature Communications</i> , 2015, 6, 7419.	12.8	149
45	Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance.. <i>Journal of Clinical Oncology</i> , 2015, 33, 509-509.	1.6	1
46	Mapping the dynamics of force transduction at cell-cell junctions of epithelial clusters. <i>ELife</i> , 2014, 3, e03282.	6.0	99
47	Oncogene-like induction of cellular invasion from centrosome amplification. <i>Nature</i> , 2014, 510, 167-171.	27.8	360
48	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. <i>Journal of Clinical Investigation</i> , 2014, 124, 2611-2625.	8.2	110
49	Into the deep: Refocusing on 3D. <i>Nature Cell Biology</i> , 2012, 14, 332-332.	10.3	5
50	In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis. <i>Journal of Visualized Experiments</i> , 2012, , .	0.3	36
51	The myosin-II-responsive focal adhesion proteome: a tour de force?. <i>Nature Cell Biology</i> , 2011, 13, 344-346.	10.3	4
52	A New Mutational activation in the PI3K Pathway. <i>Cancer Cell</i> , 2007, 12, 104-107.	16.8	230
53	Casting light on focal adhesions. <i>Nature Genetics</i> , 1998, 19, 309-311.	21.4	25